ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PRGO / earnings
AUPH (74) XNCR (47) IMNM (26) VERA (31) ⌘ Pro Terminal →

Perrigo Company plc (PRGO) Next Earnings Date & Expected ±8.1% Move

$15.75 -0.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.71

Perrigo Company plc (PRGO) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $2.19B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.75 (-0.19% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #274 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRGO compare to AUPH and XNCR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRGO?
▼

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.72 (-0.22%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Cash (8)Whales (15)SEC (5)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
$22 Bull$15 Base$12 Bear
📬 FREE PRGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRGO)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY PRGO SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (31% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 54.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$15.37+5.2% Next Q
Q2 (-2Q)
44
Grade D$16.17-0.9% Next Q
Q3 (-1Q)
46
Grade D$16.02-1.7% Next Q
Current
49
Grade D$15.75-5.4% Hist 90D α
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRGO currently carries a cautious 49/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.89) and Max Pain ($16.54) forces dealer call-delta covering toward $21.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±8.1% Swing Band

±$1.28 Expected Swing
$14.47 (-8.1%)Spot $15.75$17.03 (+8.1%)
MODEL EARNINGS SETUP GAUGE

PRGO Quantitative Pre-Earnings Setup: 49/100

Trailing EPS: $4.25 • YoY Revenue Growth: -2.8%

Model Bullish Setup (49/100)Model Risk Weight (51/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$4.25B-$1.43B$145.1M35.1%
FY 20242024-12-31$4.37B-$171.8M$244.6M35.3%
FY 20232023-12-31$4.66B-$12.7M$405.5M35.1%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRGO)

  • ✓Walkthrough of PRGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.28%📐 HORIZONTAL RANGE
2026-11-03O $15.90H $15.90L $15.75C $15.75VOL 3.35M
RES: $17.45SUP: $8.70SMA50: $14.89SMA200: $12.45
$17.31$15.16$13.02$10.88$8.73RES $17.45SUP $8.70$15.752026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRGO Butterfly Map → + Track PRGO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRGO)

Health Care Rank #274 of 1016 ⚔️ AUPH vs PRGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRGO vs. AUPH, XNCR, IMNM, VERA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Perrigo Company plc (PRGO) ranks #274 by composite RQD confidence (49/100, grade D) and #242 by equity capitalization ($2.19B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with PRGO at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRGO ACTIVE
Perrigo Company plc
D 49/100 — 35.1% -13.6% -0.19% $2.19B Benchmark Subject
AUPH
Aurinia Pharmaceuticals Inc
B 74/100 8.0x 88.5% 16.5% -3.06% $2.22B /auph-vs-prgo →
XNCR
Xencor Inc.
D 47/100 — — -21.3% -0.54% $2.22B /xncr-vs-prgo →
IMNM
Immunome Inc.
E 26/100 — — -35.0% +7.58% $2.15B /imnm-vs-prgo →
VERA
Vera Therapeutics Inc. (Class A)
E 31/100 — — -35.0% -2.36% $2.23B /vera-vs-prgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585364

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perrigo Company plc (PRGO) reported GAAP revenue of $4.25B (-2.8% vs. FY2024 revenue of $4.37B , and -8.6% cumulative change since FY2023) , GAAP net income of -$1.43B, operating cash flow of $238.5M, and free cash flow of $145.1M (-40.7% YoY). On the balance sheet, PRGO closed FY2025 with $8.54B in total assets against $3.60B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.25B -$1.43B $238.5M $145.1M $8.54B $3.60B
FY2024 (FY) 2024-12-31 $4.37B -$171.8M $362.9M $244.6M $9.65B $3.58B
FY2023 (FY) 2023-12-31 $4.66B -$12.7M $405.5M $405.5M — —

3. PRGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.75 (-0.19% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #274 in composite RQD confidence.

How does PRGO compare to AUPH and XNCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRGO?

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRGO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRGO last traded at $15.75 (-0.19% on volume of 2,007,502 shares), positioning the stock +5.78% above its 50-day simple moving average ($14.89) and +26.51% above its 200-day simple moving average ($12.45). Across its 52-week range of $9.23 to $20.65, PRGO sits at the 57.1% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($14.47 to $17.03).

Direct Sub-Reports: PRGO RQD Cockpit PRGO 12M Forecast PRGO Earnings & Move PRGO Dividends & DRIP PRGO Insiders & 13F PRGO Whale Options PRGO Profit Sankey PRGO News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRGO — Perrigo Company plc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:22Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

The PRGO scores 49 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." Pillar breakdown:

  • Fundamental Cash Engine: 8 / 20. Driven by ROIC of -13.6% and an FCF yield of 6.58%. The cash-yield figure is a supportive element, but negative ROIC indicates capital is not being earned at a return above zero.
  • Whale 13F Flow: 15 / 20. Scored on institutional accumulation and options positioning.
  • Insider Conviction: 9 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The pillar is below midpoint, indicating insider activity does not provide meaningful conviction support.
  • Macro Regime Fit: 12 / 20. Beta of 1.0 and sector sensitivity. Market-level volatility is neutral relative to the broad market.
  • Forensic Balance Sheet: 5 / 20. Altman Z of 0.2, Piotroski F of 5/9, Debt/Equity of 1.23. This is the weakest pillar and the primary driver of the low overall score; the Altman Z-Score sits in a distress-range value.

For a prospective investor, the upside case rests on the FCF yield and the institutional flow pillar; the downside case rests on negative operating and net margins, negative ROIC, a weak balance sheet pillar, and the distribution-warning verdict. Valuation appears inexpensive on the surface (dividend yield of 7. Leverage is the central tradeoff: the cash yield and dividend yield are being offset by a balance sheet pillar scoring 5 / 20.

2. Business Model, Unit Margins & SEC Financial Trajectory

Perrigo Company plc is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $2.2B.

Per the market data, gross margin is 35.1%, operating margin is -26.4%, and net margin is -33.5%. ROIC is -13.6%. The Altman Z-Score is 0.2, the Piotroski F-Score is 5/9, and Debt/Equity is 1.23. Reported revenue declined across the three periods, and operating income moved from positive in FY 2023 and FY 2024 to negative in FY 2025. The balance sheet shows reported debt of $3.60B against cash that is available only for FY 2024 ($558.8M).

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case: A 6.58% FCF yield and 7.22% dividend yield offer cash-return support at a $15.90 price despite the weak balance sheet. With Fundamental Cash Engine at 8/20 (ROIC -13.6%, FCF yield 6.58%) and Institutional Whale Flow at 15/20, sustained execution supports upside toward the top of the $9.23 – $20.65 52-week range.
  • 🐻 Primary Bear Case: Negative ROIC of -13.6%, an Altman Z of 0.2, and FY 2025 net loss of -$1.43B point to balance-sheet distress against $3.60B of debt. Investors must weigh current valuation against -26.4% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRGO carries a macro regime beta of 1.00 and gross margin of 35.1%.

  • Key Question #1: What drove the FY 2025 swing to a -$1.43B net loss and -$1.12B operating loss, and is it recurring or one-time?
  • Key Question #2: Will free cash flow conversion (6.58% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 0.20) and support upside toward the $20.65 52-week high?
  • Key Question #3: How sensitive is PRGO's 35.1% gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?

PRGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Perrigo Company plc (PRGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRGO Bull vs. Bear Conversation Board — What's Your Call at $15.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRGO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $18.78 (+19.0%)
📌 Pinned Debate

A 6.58% FCF yield and 7.22% dividend yield offer cash-return support at a $15.90 price despite the weak balance sheet.

Don't sleep on PRGO's setup in Health Care. A 6.58% FCF yield and 7.22% dividend yield offer cash-return support at a $15.90 price despite the weak balance sheet.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (49/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (35.1%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $12.15 (-23.0%)
Spot @ $15.78

Negative ROIC of -13.6%, an Altman Z of 0.2, and FY 2025 net loss of -$1.43B point to balance-sheet distress against $3.60B of debt

Fading this rally in PRGO at $15.78. Negative ROIC of -13.6%, an Altman Z of 0.2, and FY 2025 net loss of -$1.43B point to balance-sheet distress against $3.60B of debt.. With a beta of 1.0 and the stock sitting at $15.78 (52-wk range $9.23–$20.65), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%